SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing nove ...
Osivax has announced that the first patient has been vaccinated in its phase 2b clinical trial evaluating OVX836, a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback